Eli Lilly and Company $LLY Holdings Raised by ProShare Advisors LLC

ProShare Advisors LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 134,385 shares of the company’s stock after purchasing an additional 5,181 shares during the quarter. ProShare Advisors LLC’s holdings in Eli Lilly and Company were worth $155,494,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of LLY. Marshall & Sterling Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the last quarter. Foresight Capital Management Advisors Inc. bought a new stake in Eli Lilly and Company during the third quarter worth about $49,000. AlphaCentric Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $42,000. Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth $64,000. Finally, IMG Wealth Management Inc. grew its position in Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after purchasing an additional 50 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. The Goldman Sachs Group reissued a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a report on Friday. UBS Group raised their price objective on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research note on Friday. Bank of America restated a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday. Finally, Truist Financial reissued a “buy” rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,404.14.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Eli Lilly and Company Stock Down 0.4%

Shares of NYSE:LLY opened at $1,412.06 on Tuesday. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.83, a PEG ratio of 1.73 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company has a 50-day moving average price of $1,200.81 and a 200 day moving average price of $1,094.25. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,449.68.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $7.02 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last quarter. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.